Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins

Marzieh Salehi, Benedikt A. Aulinger, David A. D'Alessio

Research output: Contribution to journalReview article

78 Citations (Scopus)

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Original languageEnglish (US)
Pages (from-to)367-379
Number of pages13
JournalEndocrine Reviews
Volume29
Issue number3
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Incretins
Type 2 Diabetes Mellitus
Pharmaceutical Preparations
Cell Physiological Phenomena
Disease Progression
Insulin
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Targeting β-cell mass in type 2 diabetes : Promise and limitations of new drugs based on incretins. / Salehi, Marzieh; Aulinger, Benedikt A.; D'Alessio, David A.

In: Endocrine Reviews, Vol. 29, No. 3, 01.05.2008, p. 367-379.

Research output: Contribution to journalReview article

Salehi, Marzieh ; Aulinger, Benedikt A. ; D'Alessio, David A. / Targeting β-cell mass in type 2 diabetes : Promise and limitations of new drugs based on incretins. In: Endocrine Reviews. 2008 ; Vol. 29, No. 3. pp. 367-379.
@article{874e447a43eb425983b124d96e215053,
title = "Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins",
abstract = "Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.",
author = "Marzieh Salehi and Aulinger, {Benedikt A.} and D'Alessio, {David A.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1210/er.2007-0031",
language = "English (US)",
volume = "29",
pages = "367--379",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Targeting β-cell mass in type 2 diabetes

T2 - Promise and limitations of new drugs based on incretins

AU - Salehi, Marzieh

AU - Aulinger, Benedikt A.

AU - D'Alessio, David A.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

AB - Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

UR - http://www.scopus.com/inward/record.url?scp=43549114067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549114067&partnerID=8YFLogxK

U2 - 10.1210/er.2007-0031

DO - 10.1210/er.2007-0031

M3 - Review article

C2 - 18292465

AN - SCOPUS:43549114067

VL - 29

SP - 367

EP - 379

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 3

ER -